Krsnaa Diagnost.

Q3 FY26

Krsnaa Diagnost. Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹562

Market cap₹1.9K Cr

P/E19.2

Updated23 Aug 2026

Read4 min read

The short version

Krsnaa Diagnostics is focusing on organic growth and expects year-on-year expansion in volumes and revenues. Krsnaa Diagnostics expects growth to return in subsequent quarters after interim setbacks (Page 17).

From Krsnaa Diagnost.'s Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Krsnaa Diagnostics is focusing on organic growth and expects year-on-year expansion in volumes and revenues.
Retail segment showing strong momentum, with retail revenue growing nearly 8x YoY in Q3 FY '26, contributing 8% of total revenue; network expanded to over 3,000 touch points.
Expectation of 15-25% growth in retail touch points in coming quarters as part of strategic, long-term network building.
Rajasthan PPP project anticipated to contribute approximately INR 200 crores in revenue in FY '27, with full potential revenue expected by end of FY '27 rather than spilling into FY '28.
Core base business (ex-B2C and ex-Rajasthan) targeted to grow in the higher teens percentage-wise annually.
Both pathology and radiology segments in base business expected to grow in tandem, with potential slightly better growth in radiology next year due to new projects.

2 more points management made on revenue & sales performance

Profitability & Margins

Krsnaa Diagnostics expects growth to return in subsequent quarters after interim setbacks (Page 17).
Retail segment showed strong potential with 8x YoY growth in Q3 FY '26 and expanding network of 3,000+ touch points, expected to scale steadily (Page 7).
The business model remains intact, with selective tender participation and cautious capital allocation ensuring disciplined growth (Page 17).
Return to breakeven for retail business is anticipated by Q4 (Page 7).
Revenue growth in base business (excluding Rajasthan and retail) is aspirationally targeted in the higher teens percentage annually (Page 10).
Expansion projects like Rajasthan and Maharashtra contribute to future revenue; pathology share expected to increase possibly to 65-70% of revenue (Page 16).

2 more points management made on profitability & margins

See what Krsnaa Diagnost. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Maharashtra MRI project: Ongoing capex incurred, but revenue delayed due to site and compliance clearance delays; 10 MRI sites nearing inauguration expected in Q4 FY26.
Rajasthan project: Around 20 labs installed, 300 collection centers in progress; majority expected by Q4 FY26 with some spillover into Q1 FY27; involves capital investment with front-loaded expenses.
Selective tender participation: Management is cautious and selective about new PPP tenders, focusing on projects with clearances and feasibility to ensure capital discipline.

- Strategic alignment with Apulki Hospital (specialized cancer and cardiac care): Long-term investment aligning with oncology specialty business, expecting 60 years of revenue visibility. - Finance leases for two machines: Minor capital investment through lease financing with minimal impact on financing costs. Overall, capital allocation remains disciplined, with investments focused on long-term, high-quality growth projects.

2 more points management made on capital expenditure plans

Fundraising & Capital Structure

There is a mention of debt raising specifically for the Rajasthan project, with a facility from ADB in the final stages of completion (Page 15).
The management will inform about any debt raised, emphasizing that the debt is project-specific and not on the overall company debt (Page 15).
Interest expense is expected to go down due to collections and working capital management, with no significant increase anticipated from finance leases (Page 14).

2 more points management made on fundraising & capital structure

See what Krsnaa Diagnost. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Krsnaa Diagnostics is selective about the PPP projects it undertakes, focusing on tenders that can be successfully delivered.
The largest rollout currently underway is the Rajasthan project.
Apart from Rajasthan and Maharashtra radiology tender under implementation, there are a couple of other projects in the pipeline.
No major new order wins have occurred in the past 12 months except Rajasthan tender.

2 more points management made on order book & pipeline

Krsnaa Diagnost. — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹173 Cr, net profit ₹43 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Krsnaa Diagnost.'s management said in earlier quarters

Others in Healthcare Services this season

Vijaya Diagnost. (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnost.'s Q3 FY26 earnings call — and…
Aster DM Quality (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
Chandan Healthcare Ltd (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
Rainbow Child. (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Krsnaa Diagnost. Q3 FY26 results?

What is Krsnaa Diagnost. share price analysis?

Krsnaa Diagnost. currently shows a neutral. The stock trades at a P/E of 19.1 with a market cap of ₹1,866 Cr. Investors should review the full earnings analysis for detailed insights.

Is Krsnaa Diagnost. planning capital expenditure?

Maharashtra MRI project: Ongoing capex incurred, but revenue delayed due to site and compliance clearance delays; 10 MRI sites nearing inauguration expected in Q4 FY26.

Keep Krsnaa Diagnost. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.